Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06534437

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) (JASPIS-01)

An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Sponsor: Menarini Group

Conditions Non-Hodgkin Lymphoma, B-cell

Interventions Glofitamab MEN1703

Updated 7 times since 2024 Last updated: Sep 23, 2025 Started: Dec 5, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06534437, this PHASE2 trial focuses on Non-Hodgkin Lymphoma, B-cell and remains actively recruiting participants. Sponsored by Menarini Group, it has been updated 7 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
May 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Feb 2025 — May 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Dec 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Menarini Group
Ryvu Therapeutics SA

Data source: Ryvu Therapeutics SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Biała Podlaska, Poland , Bydgoszcz, Poland , Gdansk, Poland , Gdynia, Poland , Glasgow, United Kingdom , Gliwice, Poland , Katowice, Poland , Krakow, Poland , Le Mans, France and 21 more locations